News
IMNN
1.400
-1.41%
-0.020
IMNN: Promising Preclinical Results for PLACCINE Platform…
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Update on SARS-CoV-2 Vaccine Candidate Imunon, Inc. (NASDAQ:IMNN) is currently conducting a non-human primate (NHP) challenge study with the company’s DNA-based approach for...
Zacks Small Cap Research · 1d ago
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
LAWRENCEVILLE, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer and Mr. Jeffrey Church, Executive Vice President ...
GlobeNewswire · 11/22 13:30
Imunon falls 4% on wider-than-expected loss
Seekingalpha · 11/14 19:35
BRIEF-Imunon Reports Q3 Financial Results, Provides Business Update
Reuters · 11/14 17:35
Imunon, Inc. - Common Stock Q3 EPS $(0.87) Misses $(0.81) Estimate
Benzinga · 11/14 13:00
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announ...
GlobeNewswire · 11/14 13:00
Notable earnings before Monday's open
Seekingalpha · 11/11 14:23
BRIEF-Imunon Enters Into Technology Evaluation Agreement With Acuitas Therapeutics
Reuters · 11/10 14:38
IMUNON Enters Into Technology Evaluation Agreement With Acuitas Therapeutics To Evaluate IMUNON's PLACCINE Plasmid DNA With Acuitas' Lipid Nanoparticle Delivery System
Benzinga · 11/10 13:38
Alliance Global Partners Initiates Coverage On Imunon with Buy Rating, Announces Price Target of $15
Alliance Global Partners analyst James Molloy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating and announces Price Target of $15.
Benzinga · 10/13 14:46
--Alliance Global Starts Imunon at Buy with $15 Price Target
--Alliance Global Starts Imunon at Buy with $15 Price Target
MT Newswires · 10/13 11:37
BRIEF-Imunon Appoints James E. Dentzer To Its Board Of Directors
BRIEF-Imunon Appoints James E. Dentzer To Its Board Of Directors
Reuters · 10/03 21:03
Imunon Reports Partial Results From Ongoing Non-human Primate Study
Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, reports that partial results from an ongoing non-human primate study designed to examine the immunogenicity of its proprietary PLACCINE
Benzinga · 10/03 12:04
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s...
GlobeNewswire · 09/29 21:00
Celsion changes name to Imunon (IMNN)
Celsion (NASDAQ:CLSN) <a href="https://seekingalpha.com/pr/18944590-...
Seekingalpha · 09/19 20:36
Celsion Corporation Announces Company Name Change to Imunon, To Trade Under Symbol 'IMNN' Effective As Of Sept. 21
Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company&#39;s business focus and its
Benzinga · 09/19 20:32
Celsion Corporation Announces Company Name Change to Imunon, Inc.
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today ...
GlobeNewswire · 09/19 20:30
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Benzinga · 09/15 22:47
Celsion Completes Enrollment Of The Phase I/II OVATION 2 Study With GEN-1 In Advanced Ovarian Cancer
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion
Benzinga · 09/15 12:36
Celsion Completes Enrollment for Phase 1/2 Trial with GEN-1 in Ovarian Cancer; Shares Rise
Celsion Completes Enrollment for Phase 1/2 Trial with GEN-1 in Ovarian Cancer; Shares Rise
MT Newswires · 09/15 10:59
More
Webull provides a variety of real-time IMNN stock news. You can receive the latest news about Imunon Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMNN
Imunon, Inc., formerly Celsion Corporation, is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials. Its lead clinical program GEN-1, a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. GEN-1 works by instructing the body to produce cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. The Company has two platform technologies: TheraPlas platform for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies, and its PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. Its platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices.